ライフサイエンスコーパス: heart failure

1 bradycardia, bronchospasm, and/or congestive heart failure).

2 as a critical determinant of arrhythmias in heart failure.

3 structural remodeling of chromatin underpins heart failure.

4 f 10 patients with CHD with AF had developed heart failure.

5 ardiomyopathy (DCM) is an important cause of heart failure.

6 l hypertension, obstructive sleep apnoea and heart failure.

7 ive therapy in older patients with ischaemic heart failure.

8 onto obesity-related cardiac remodeling and heart failure.

9 apy of choice for all patients with advanced heart failure.

10 tation is an effective therapy for end-stage heart failure.

11 modeling process, is a major risk factor for heart failure.

12 is considered a target for the treatment of heart failure.

13 nostic workup and treatment of patients with heart failure.

14 e with a first-time in-hospital diagnosis of heart failure.

15 ce hospitalization and mortality in systolic heart failure.

16 h as ventricular fibrillation and congestive heart failure.

17 ted the incidence and the mortality rates of heart failure.

18 lic target in a number of diseases including heart failure.

19 ptides decline with obesity in patients with heart failure.

20 eling response, which can ultimately lead to heart failure.

21 eutic target for pathological remodeling and heart failure.

22 generation of stem cell-based treatment for heart failure.

23 likelihood of depression in outpatients with heart failure.

24 T were among the top predictors for incident heart failure.

25 for morbidity and mortality in patients with heart failure.

26 by hyperglycemia is a major risk factor for heart failure.

27 to limiting progression of this condition to heart failure.

28 y, sleep disordered breathing and congestive heart failure.

29 s such as myocardial infarction, stroke, and heart failure.

30 urrently intensely studied as a biomarker in heart failure.

31 evated hs-TnT were older and had more severe heart failure.

32 MACE, including cardiovascular mortality and heart failure.

33 diseases, including cardiac hypertrophy and heart failure.

34 ion in t-tubule organization and accelerated heart failure.

35 nfarction, stroke, or hospital admission for heart failure.

36 and over time, these chronic loads can cause heart failure.

37 normalities, including pericardial edema and heart failure.

38 ht further improve outcomes in patients with heart failure.

39 of respiratory and autonomic dysfunction in heart failure.

40 ive hypertrophic cardiomyopathy and advanced heart failure.

41 g these CpGs novel epigenetic biomarkers for heart failure.

42 myocardial infarction, ischemic stroke, and heart failure.

43 iotensin system inhibitors for patients with heart failure.

44 sibility remains unresolved in patients with heart failure.

45 on (1.55, 1.33-1.80), hospital admission for heart failure (1.59, 1.36-1.86) and all-cause death (1.1

46 Mean CHADS-VASc score was 3.0 (heart failure, 1.4%; hypertension, 54%; diabetes mellitu

47 lar events (CVEs) including 281 (23.8%) with heart failure, 109 (9.2%) with atrial fibrillation, 89 (

48 e the most common noncardiac causes, whereas heart failure (22.5%) and arrhythmias (6.6%) were the mo

49 A), and cBIN1 level decreased in humans with heart failure, a condition with reduced cardiac muscle c

50 530 771, and 1 125 231 hospitalizations for heart failure, acute myocardial infarction, and pneumoni

51 Acute decompensated heart failure (ADHF) requiring hospitalization is associ

52 of patients discharged from a previous acute heart failure admission.

53 r the composite outcome of incident ASCVD or heart failure after further stratifying by CAC (0, 1-100

54 ated with mortality or rehospitalization for heart failure after multivariate adjustment were increas

55 5'-nucleotidase (CD73) on the development of heart failure after transverse aortic constriction (TAC)

56 n is associated with worse outcomes in acute heart failure (AHF).

57 istration of MSCs should improve outcomes in heart failure, an entity in which excessive chronic infl

58 osis development that can ultimately lead to heart failure and arrhythmias.

59 d that excessive leukocyte invasion leads to heart failure and death during acute myocardial ischemia

60 n increasingly considered as a main cause of heart failure and death in diabetic patients.

61 ardial infarction (MI) is a leading cause of heart failure and death worldwide.

62 f cardiovascular events may be enhanced when heart failure and glucose intolerance coexist and may be

63 served ejection fraction along with signs of heart failure and hence were diagnosed with HFpEF.

64 activation is an independent risk factor for heart failure and is considered a target for the treatme

65 Both heart failure and myocardial infarction increase risk of

66 People with heart failure and preserved ejection fraction develop in

67 5) and in a pig model with features of human heart failure and preserved ejection fraction with stern

68 in the treatment of subsets of patients with heart failure and pulmonary hypertension.

69 and pathophysiology of aortic stenosis with heart failure and reduced ejection fraction and summariz

70 METHODS AND Patients with heart failure and reduced ejection fraction under optima

71 initiated significantly later with comorbid heart failure and renal failure, with absence of fever o

72 rterial hypertension, diabetes mellitus, and heart failure), and a lower risk for 10-year mortality,

73 heart disease, 1.20 (95% CI: 1.01, 1.42) for heart failure, and 1.11 (95% CI: 1.04, 1.19) for a compo

74 ese risk markers in coronary artery disease, heart failure, and atrial fibrillation is discussed in d

75 high risk of cardiovascular disease, stroke, heart failure, and atrial fibrillation.

76 re myocardial infarction, stroke, congestive heart failure, and cardiovascular mortality.

77 inked to development of atrial fibrillation, heart failure, and death.

78 Older age, congestive heart failure, and greater left ventricular dilation at

79 atal or nonfatal stroke, hospitalization for heart failure, and hospitalization for acute coronary sy

80 CM but for both groups older age, congestive heart failure, and increased left ventricular end-systol

81 uding risk of myocardial infarction, stroke, heart failure, and major cardiovascular events.

82 Incident CVD included CHD, stroke, heart failure, and peripheral arterial disease.

83 ar disease (including myocardial infarction, heart failure, and stroke) and all-cause mortality were

84 coronary insufficiency, index admission for heart failure, and stroke.

85 tension, coronary heart disease, arrhythmia, heart failure, and stroke.

86 onal Class III or IV, previous admission for heart failure, and valve disease) and non-cardiac variab

87 onary artery (PA) pressures in patients with heart failure are associated with a high risk for hospit

88 ing the progression of diabetes mellitus and heart failure are closely intertwined, such that worseni

89 mammal (rat) and a large mammal (human) with heart failure are shown, demonstrating myocardial slice

90 89), currently in phase 3 trials for chronic heart failure, are now reported.

91 respectively, and repeat hospitalization for heart failure at 1 year occurred in 20.2%.

92 ar, and noncardiovascular mortality, MI, and heart failure at different levels of troponins.

93 cardial samples from patients with end-stage heart failure at time of transplant, with or without dia

94 uded myocardial infarction, new or worsening heart failure, atrial fibrillation, stroke, deep venous

95 penoid used in the treatment of glaucoma and heart failure based on its activity as a cyclic AMP boos

96 0 individuals with a first-time diagnosis of heart failure between 1995 and 2012; the annual incidenc

97 sity was associated with all-cause death and heart failure, but the result was not significant (P=0.0

98 hetic stimulation have been reported in left heart failure, but whether it would be beneficial for pu

99 ardiac surgery, anemia, respiratory failure, heart failure, cardiac arrest, metastatic cancer (requir

100 the evaluation of congenital heart disease, heart failure, cardiac masses, pericardial disease, and

101 implementing, and monitoring improvement in heart failure care.

102 The estimated absolute number of prevalent heart failure cases in the UK increased even more, by 23

103 -infected individuals have excess congestive heart failure (CHF) risk compared with uninfected people

104 rdiac dysfunction in both normal and chronic heart failure (CHF) states remains unknown.

105 hmias, eclampsia or preeclampsia, congestive heart failure (CHF), length of stay, preterm labor, anem

106 ere chronic kidney disease (CKD), congestive heart failure (CHF), or chronic liver disease (CLD) with

107 dence and contribute to mortality in chronic heart failure (CHF).

108 aggerated global sympathetic tone in chronic heart failure (CHF).

109 l strategies for Management of Patients with Heart failure) clinical cohort study, 496 patients with

110 Once established, heart failure commonly results in mortality.

111 bypass surgery leads to a lower incidence of heart failure compared with intensive lifestyle modifica

112 tes mellitus) are characteristic features of heart failure; conversely, neurohormonal systems activat

113 RATIONALE: In patients with chronic heart failure, daytime oscillatory breathing at rest is

114 had a higher rate of hospital admission for heart failure decompensation in follow-up (HR, 1.66; 95%

115 pital status, known coronary artery disease, heart failure, diabetes mellitus, chronic kidney disease

116 noninvasive telemonitoring in patients with heart failure does not reduce mortality or hospitalizati

117 in greater improvements in QoL compared with heart failure education (P<0.01), including the Kansas C

118 e randomized to either a CST intervention or heart failure education, both delivered over 16 weeks.

119 al of 30% to 40% of patients with congestive heart failure eligible for cardiac resynchronization the

120 llitus, history of stroke, >1 g proteinuria, heart failure, estimated glomerular filtration rate <20

121 tential myocardial infarctions, strokes, and heart failure events in HealthLNK and compared them with

122 diovascular death, 17.5 versus 2.6, P<0.001; heart failure events, 22.4 versus 7.4, P<0.001); these r

123 We assumed no heart failure for patients aged 15 years or younger and

124 Heart failure guidelines recommend routine monitoring of

125 hospital quartile of ICU use for congestive heart failure had a sensitivity of 50-60% and specificit

126 Approximately half of patients with heart failure have preserved ejection fraction.

127 le is known whether PH heightens the risk of heart failure (HF) admission or mortality among chronic

128 r, molecular pathways underlying accelerated heart failure (HF) after MI in T2DM remain unclear.

129 nthracycline chemotherapy is associated with heart failure (HF) among survivors of non-Hodgkin lympho

130 Patients with heart failure (HF) and atrial fibrillation (AF) have hig

131 Cardiorenal syndrome is common in acute heart failure (HF) and portends poor prognosis.

132 Although heart failure (HF) disproportionately affects older adul

133 To assess the current landscape of the heart failure (HF) epidemic and provide targets for futu

134 Patients with heart failure (HF) have high mortality and mobility.

135 n between preterm birth and risk of incident heart failure (HF) in children and young adults.

136 idosis (ATTR) is an underrecognized cause of heart failure (HF) in older individuals, owing in part t

137 It is unknown whether the increased risk of heart failure (HF) in rheumatoid arthritis (RA) is indep

138 Prevalence of heart failure (HF) increases significantly with age, coi

139 Heart failure (HF) is a chronic disease that compromises

140 Heart failure (HF) is a complex syndrome associated with

141 Timely follow-up after hospitalization for heart failure (HF) is recommended.

142 l preparations isolated from human donor and heart failure (HF) left ventricle.

143 dorff-perfused hearts from control (CTL) and heart failure (HF) mice (HF induced by transaortic const

144 Sleep apnea is common in hospitalized heart failure (HF) patients and is associated with incre

145 ABSTRACT: Heart failure (HF) patients with preserved ejection frac

146 hod to assess the impact of interventions on heart failure (HF) patients' functional status.

147 Heart failure (HF) prevalence in arrhythmogenic right ve

148 unclear how patients hospitalized for acute heart failure (HF) who are long-term chronic HF survivor

149 Heart failure (HF) with preserved ejection fraction (HFp

150 enic role of ischemic heart disease (IHD) in heart failure (HF) with reduced ejection fraction (HFrEF

151 ath, hospitalization, thromboembolic events, heart failure (HF), and AF progression.

152 therapy are known to have increased risks of heart failure (HF), but a radiation dose-response relati

153 Atrial fibrillation (AF) is common in heart failure (HF), but the outcome by type of AF is lar

154 olute rates and risk differences of incident heart failure (HF), coronary heart disease (CHD), and st

155 In heart failure (HF), energy metabolism pathway in cardiac

156 c sympathetic overstimulation, a hallmark of heart failure (HF), induces pathological signaling throu

157 or acute myocardial infarction (AMI) without heart failure (HF), it is unclear if beta-blockers are a

158 -blockers increase survival in patients with heart failure (HF), the mechanisms behind this protectio

159 extensively studied in patients with chronic heart failure (HF), with only limited success.

160 promote cardiac fibrosis (CF) in nonischemic heart failure (HF).

161 ion between ST2 and outcome in patients with heart failure (HF).

162 ammatory response predicts worse outcomes in heart failure (HF).

163 I) are independently associated with risk of heart failure (HF).

164 a are central tenets of patient education in heart failure (HF).

165 tic tool for the diagnosis and management of heart failure (HF).

166 the association between CRF and incidence of heart failure (HF).

167 mising therapeutic approach for treatment of heart failure (HF).

168 flammation is a hallmark of chronic ischemic heart failure (HF); however, the pathophysiological role

169 3; 95% CI: 0.07 to 0.75), total mortality or heart failure hospitalization (aHR: 0.32; 95% CI: 0.12 t

170 y end point or day-30 all-cause mortality or heart failure hospitalization rate differed between the

171 Rates of heart failure hospitalization remain unacceptably high.

172 ur-year survival that is free from death and heart failure hospitalization was higher for adherent pa

173 including myocardial infarction, stroke, and heart failure hospitalization, were compared between pat

174 with improvements in all-cause mortality or heart failure hospitalization.

175 occurrence of cardiovascular events (death, heart failure, hospitalization, arrhythmia, thromboembol

176 Improvements in both survival and heart failure hospitalizations with CRT-D were greatest

177 ), age (HR, 1.02, P = .001), and preexisting heart failure (HR, 1.85, P < .001) independently predict

178 rmal' range) showed strong associations with heart failure (HR: 2.04; 95% confidence interval [CI]: 1

179 s a potential pharmacotherapeutic target for heart failure, hypertension, and other cardiovascular di

180 outcomes were myocardial infarction, angina, heart failure, hypertension, arrhythmias, arterioscleros

181 measure mortality at 1 year in patients with heart failure in Africa, China, India, the Middle East,

182 essed cardiac hypertrophy and progression to heart failure in both vitamin D deficient and normal mic

183 ty rates following a first-time diagnosis of heart failure in Denmark between 1995 and 2012.

184 Depletion of CTCF was sufficient to induce heart failure in mice, and human patients with heart fai

185 tation in food attenuates the development of heart failure in mice, more robustly in DCM, and partial

186 membrane oxygenation for acute decompensated heart failure in our ICU (67% of them had an intraaortic

187 tion therapy (CRT) is a potent treatment for heart failure in the setting of ventricular dyssynchrony

188 From 2002 to 2014, heart failure incidence (standardised by age and sex) de

189 ian of 4.1 years, surgery patients had lower heart failure incidence than lifestyle modification pati

190 ty and gap junction coupling, as observed in heart failure, increase the probability of extreme DADs

191 bination drug recently approved for treating heart failure, inhibits stretch-induced hypertrophy, and

192 pitalization for management of decompensated heart failure, initiation of mechanical circulatory supp

193 Here, in the International Congestive Heart Failure (INTER-CHF) study, we aimed to measure mor

194 Heart failure is common in adults, accounting for substa

195 Specifically, the risk of developing heart failure is higher in patients with diabetes or obe

196 adily available oral iron supplementation in heart failure is unknown.

197 promise to expand the use of pressure-guided heart failure management.

198 resulting cerebral small vessel disease and heart failure may contribute to early cognitive decline

199 ents had persisting symptoms compatible with heart failure (median of 13 [range 0-76] in the Minnesot

200 pharmacotherapies for African Americans (eg, heart failure medications), disease management is less e

201 The authors hypothesized that the Seattle Heart Failure Model (SHFM) for overall survival and the

202 evant prediction models exist (SHFM [Seattle Heart Failure Model] and HMRS [HeartMate II Risk Score])

203 safety endpoint were age, anemia, congestive heart failure, multivessel disease, number of stents imp

204 rment has been detected in cardiomyopathies, heart failure, myocardial ischaemia, and hypertrophy.

205 iritide in Patients With Acute Decompensated Heart Failure; NCT00475852).

206 nversely, neurohormonal systems activated in heart failure (norepinephrine, angiotensin II, aldostero

207 precursors, could be useful for treatment of heart failure, notably in the context of DCM, a disease

208 ter 1 year was related to a hazard ratio for heart failure of 0.77 (95% confidence interval, 0.60-0.9

209 point was defined as symptomatic congestive heart failure of New York Heart Association class III or

210 more pronounced in patients with congestive heart failure or ischemic heart disease than in those wi

211 acute coronary syndrome, stroke, congestive heart failure, or CVD death), and (ii) serious adverse e

212 malignant ventricular arrhythmias, end-stage heart failure, or death) compared with carriers of other

213 ed to predict myocardial infarction, stroke, heart failure, or death.

214 he hospital for acute myocardial infarction, heart failure, or pneumonia.

215 er risk of dying from myocardial infarction, heart failure, or stroke, respectively, than members of

216 ent myocardial infarction, stent thrombosis, heart failure, or target vessel revascularization.

217 m creatinine increases in predicting adverse heart failure outcomes.

218 esented with rapid development of congestive heart failure over 6 months, in sharp contrast to a prev

219 vascular disease, myocardial infarction, and heart failure over use of established and novel cardiova

220 TnT levels in patients with chronic ischemic heart failure (P=0.0008, n=10, triple measurements).

221 Innate and adaptive immune cells modulate heart failure pathogenesis during viral myocarditis, yet

222 d inflammation is the primary determinant in heart failure pathology post-MI.

223 essure to Improve Outcomes in NYHA Class III Heart Failure Patients [CHAMPION]; NCT00531661).

224 A significant proportion of heart failure patients do not demonstrate clinical impro

225 ement) demonstrated that ambulatory advanced heart failure patients selected for left ventricular ass

226 Forty consecutive heart failure patients underwent planar acquisition 4 h

227 orthogonal to the main LV flow direction in heart failure patients with LBBB compared to those witho

228 MRI data were acquired in heart failure patients with LBBB or matched patients wit

229 d in improvement of patient health status in heart failure patients with low self-reported hrQoL, but

230 tients with left bundle branch block (LBBB), heart failure patients with narrow QRS and nonspecific i

231 ew York Heart Association class IV (NYHA IV) heart failure patients.

232 al differences in mortality in patients with heart failure persisted after multivariable adjustment f

233 hy, patients develop a persistent, long-term heart failure phenotype.

234 ffects with respect to rescuing the cellular heart failure phenotype.

235 optimal cell population(s) for treatment of heart failure prompted implementation of a protocol for

236 w-up; p < 0.0001 vs. baseline) and Minnesota Heart Failure Questionnaire scores (56.2 +/- 26.8 vs. 31

237 13 [range 0-76] in the Minnesota Living with Heart Failure Questionnaire) and cardiac limitation on e

238 ts: ejection fraction, Minnesota Living with Heart Failure Questionnaire, 6-min walk test, major adve

239 art failure in mice, and human patients with heart failure receiving mechanical unloading via left ve

240 g Hospital Admission for Acute Decompensated Heart Failure Reduce Mortality and Readmissions?) demons

241 ng patients from the Get With the Guidelines Heart Failure registry with Medicare data.

242 ving Treatment in Hospitalized Patients with Heart Failure) registry, 6,286 had a stable heart rate,

243 ictims remain at risk for infarct expansion, heart failure, reinfarction, repeat revascularization, a

244 Heart failure-related hospital readmissions and mortalit

245 A damage and its role in the pathogenesis of heart failure remain elusive.

246 unction, such as conduction defect, DCM, and heart failure, remains unclear.

247 r 2 inhibitors may reduce cardiovascular and heart failure risk in patients with type 2 diabetes mell

248 Although heart failure risk models perform reasonably well at the

249 AKI associated with a 58% increased risk of heart failure (RR 1.58; 95% CI, 1.46 to 1.72) and a 40%

250 (RR: 0.67; 95% CI: 0.45 to 0.98), and 37% in heart failure (RR: 0.63; 95% CI: 0.43 to 0.99) compared

251 sus 29 kg/m(2)), worse Minnesota Living With Heart Failure score (48 versus 40), higher median N-term

252 In human heart failure, Ser199 (equivalent to Ser200 in mouse) of

253 rtions of patients of black race, those with heart failure signs at admission, and bleeding complicat

254 expertise from interventional cardiologists, heart failure specialists, cardiac surgeons, and cardiac

255 ry hypertension across the broad spectrum of heart failure stages.

256 The risk of heart failure, stroke, or retinopathy, or prevalent fast

257 ses (acute myocardial infarction, congestive heart failure, stroke, pneumonia, and chronic obstructiv

258 death, nonfatal myocardial infarction [MI], heart failure, stroke, transient ischemic attack, periph

259 cute Congestion with Tolvaptan in Congestive Heart Failure) study was conducted to address the acute

260 uestionnaires were used to collect data: the Heart Failure Symptom Survey, the Interpersonal Support

261 ong individual and clinical characteristics, heart failure symptomatology, and subcomponents of socia

262 her individual and clinical characteristics, heart failure symptomatology, and the subcomponents of s

263 strain and Ea were associated with worsening heart failure symptoms at 1 year.

264 myopathy is an increasingly recognized acute heart failure syndrome precipitated by intense emotional

265 er among patients with a recent diagnosis of heart failure than among those with a longer-standing di

266 utic options for initial surgery and chronic heart failure that results from failed palliation are li

267 In heart failure, the beta-adrenergic receptors (betaARs) b

268 e randomly assigned 2157 patients with acute heart failure to receive a continuous intravenous infusi

269 We randomly assigned patients with advanced heart failure to receive either the new centrifugal cont

270 tor that is currently in clinical trials for heart failure treatment.

271 ata collected in the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT), which randomly assigned

272 vascular Improvements With MV-ASV Therapy in Heart Failure) trial investigated whether minute ventila

273 Effectiveness of Nesiritide in Decompensated Heart Failure) trial randomized 7,141 hospitalized patie

274 Impact on Global Mortality and Morbidity in Heart Failure) trial randomly assigned 8399 patients wit

275 l strategies for Management of Patients with Heart failure [TRIUMPH]; NTR1893).

276 In patients with acute heart failure, ularitide exerted favorable physiological

277 mpaired cardiac force-frequency response and heart failure under some conditions but the mechanisms a

278 with recurrence and mortality were advanced heart failure, VT cycle length, and a left-sided-only pr

279 PANWARDS (platelets, albumin, no congestive heart failure, warfarin, age, race, diastolic blood pres

280 is probably due to immunosenescence, because heart failure was associated with increased senescent CD

281 point of death, transplant, or admission for heart failure was reached in 88 patients.

282 associated with incident kidney failure and heart failure, we estimated GSTM1 copy number using exom

283 erved ejection fraction (HFpEF) (EF >/=50%), heart failure with borderline ejection fraction (HFbEF)

284 aptan in Patients Hospitalized for Worsening Heart Failure With Challenging Volume Management [SECRET

285 es in outcomes in patients hospitalized with heart failure with preserved ejection fraction (HFpEF) (

286 Heart failure with preserved ejection fraction (HFpEF) i

287 KEY POINTS: Heart failure with preserved ejection fraction (HFpEF) i

288 gh left atrial (LA) dysfunction is common in heart failure with preserved ejection fraction (HFpEF),

289 ts with hypertensive heart disease (HHD) and heart failure with preserved ejection fraction (HFpEF).

290 METHODS AND We randomized 12 subjects with heart failure with preserved ejection fraction to oral K

291 comes in the I-Preserve trial (Irbesartan in Heart Failure With Preserved Ejection Fraction) accordin

292 In heart failure with preserved ejection fraction, patients

293 ection fraction (HFbEF) (EF 41% to 49%), and heart failure with reduced ejection fraction (HFrEF) (EF

294 the first study to evaluate elamipretide in heart failure with reduced ejection fraction and demonst

295 lly over time among ambulatory patients with heart failure with reduced ejection fraction who were en

296 efficacy of many therapies for patients with heart failure with reduced ejection fraction, such as an

297 garding all-cause mortality in patients with heart failure with reduced ejection fraction.

298 s, are under investigation for patients with heart failure with reduced left ventricular ejection fra

299 resent in approximately 50% of patients with heart failure with reduced left ventricular ejection fra

300 there was an initial decrease in PAC use in heart failure, with a nadir in 2009 followed by a subseq